In regards to negative data for AIPAC, this is very much a real concern and I agree. However I think the downside is somewhat covered by the trials being done in melanoma, head and neck and lung cancer. The downside of potential negative AIPAC data will further be mitigated if the upcoming TACTI-002 update shows that regardless of PD-L1 status, that efti can make keytruda work for a broader spectrum of NSCLC patients.
If AIPAC is negative, the SP will no doubt take a hit- but other trials will cover IMM sufficiently.
Having said that, on the balance of probabilities, I think AIPAC will be positive. In all historical studies, paclitaxel as a monotherapy isn't great (PFS of circa 5.8 months). And all the information we know on the combo is that it delays cancer progression well (3/30 patients in the phase 1 had progressed by 6 months, 87% DCR in the ph2 lead up trial).
IMM Price at posting:
30.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)